| Source: |
Edsjö, A, Russnes, H G, Lehtiö, J, Tamborero, D, Hovig, E, Stenzinger, A, Rosenquist, R, Janowska, A, Rioja, A L P, Stenzinger, A, Razzak, A, Edsjö, A, Lepland, A, Marra, A, Planken, A, Helland, Å, Patocs, A, Mainoli, B, Ryll, B, Brasiuniene, B, Kazdal, D, Tamborero, D, Cerina, D, Hult, E H, Baltruškevičienė, E, Vrdoljak, E, Hovig, E, Chavarria, E, Garralda, E, Aas, E, Bjørgo, E, Voest, E, Curigliano, G, Fagereng, G L, Gelderblom, H, Russnes, H G, Verheul, H, Timmer, H, Brana, I, Lugowska, I, Lehtiö, J, Blay, J-Y, Oliveira, J, Rekker, K, Toome, K, Jalkanen, K, Taskén, .... |
| Description: |
In the last decades, the development of high-throughput molecular assays has revolutionised cancer diagnostics, paving the way for the concept of personalised cancer medicine. This progress has been driven by the introduction of such technologies through biomarker-driven oncology trials. In this review, strengths and limitations of various state-of-the-art sequencing technologies, including gene panel sequencing (DNA and RNA), whole-exome/whole-genome sequencing and whole-transcriptome sequencing, are explored, focusing on their ability to identify clinically relevant biomarkers with diagnostic, prognostic and/or predictive impact. This includes the need to assess complex biomarkers, for example microsatellite instability, tumour mutation burden and homologous recombination deficiency, to identify patients suitable for specific therapies, including immunotherapy. Furthermore, the crucial role of biomarker analysis and multidisciplinary molecular tumour boards in selecting patients for trial inclusion is discussed in relation to various trial concepts, including drug repurposing. Recognising that today's exploratory techniques will evolve into tomorrow's routine diagnostics and clinical study inclusion assays, the importance of emerging technologies for multimodal diagnostics, such as proteomics and in vivo drug sensitivity testing, is also discussed. In addition, key regulatory aspects and the importance of patient engagement in all phases of a clinical trial are described. Finally, we propose a set of recommendations for consideration when planning a new precision cancer medicine trial. |